CR20250057A - PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE - Google Patents

PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE

Info

Publication number
CR20250057A
CR20250057A CR20250057A CR20250057A CR20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A
Authority
CR
Costa Rica
Prior art keywords
compositions
antibody
pharmaceutical composition
disorder
mediated disease
Prior art date
Application number
CR20250057A
Other languages
Spanish (es)
Inventor
Aleksandra Aleksandrovna Sozonova
Dmitry Valentinovich Morozov
Ekaterina Aleksandrovna Lomkova
Aleksandr Olegovich Iakovlev
Arina Valerevna Zinkina-Orikhan
Daria Dmitrievna Bolsun
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022127768A external-priority patent/RU2824627C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CR20250057A publication Critical patent/CR20250057A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo de la farmacia y la medicina, específicamente a composiciones farmacéuticas de anticuerpo anti-CD20, en particular divozilimab, cuyas composiciones pueden utilizarse para tratar una enfermedad o trastorno mediado por CD20. La invención se refiereademás al uso de dichas composiciones para el tratamiento de una enfermedad o trastorno mediado por CD20, así como a un método de tratamiento de una enfermedad o trastorno mediado por CD20, que comprende la administración de dichas composiciones.The present invention relates to the field of pharmacy and medicine, specifically to anti-CD20 antibody pharmaceutical compositions, in particular divozilimab, which compositions can be used to treat a CD20-mediated disease or disorder. The invention further relates to the use of such compositions for the treatment of a CD20-mediated disease or disorder, as well as to a method of treating a CD20-mediated disease or disorder, comprising the administration of such compositions.

CR20250057A 2022-07-26 2023-07-17 PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE CR20250057A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2022120466 2022-07-26
RU2022127768A RU2824627C2 (en) 2022-10-26 Pharmaceutical composition of anti-cd20 antibody and use thereof
PCT/RU2023/050174 WO2024025440A1 (en) 2022-07-26 2023-07-17 Pharmaceutical composition of anti-cd20 antibody and use thereof

Publications (1)

Publication Number Publication Date
CR20250057A true CR20250057A (en) 2025-08-13

Family

ID=89707083

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250057A CR20250057A (en) 2022-07-26 2023-07-17 PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE

Country Status (14)

Country Link
CN (1) CN119997972A (en)
AR (1) AR130008A1 (en)
CL (1) CL2025000215A1 (en)
CR (1) CR20250057A (en)
DO (1) DOP2025000008A (en)
JO (1) JOP20250015A1 (en)
MA (1) MA70850A1 (en)
MX (1) MX2025000682A (en)
PE (1) PE20251691A1 (en)
PY (1) PY2357704A (en)
TW (1) TW202417044A (en)
UY (1) UY40364A (en)
WO (1) WO2024025440A1 (en)
ZA (1) ZA202500495B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247408A1 (en) * 2024-05-31 2025-12-04 百奥泰生物制药股份有限公司 Use of anti-cd20 antibody or antigen-binding fragment thereof in treatment of diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
JP7027321B2 (en) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド Subcutaneous preparation of anti-CD38 antibody and its use
RU2724469C2 (en) * 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds to cd20
CN114555117A (en) * 2019-10-12 2022-05-27 百奥泰生物制药股份有限公司 anti-CD 20 antibody preparation and application of anti-CD 20 antibody in treatment of CD20 positive diseases

Also Published As

Publication number Publication date
WO2024025440A1 (en) 2024-02-01
AR130008A1 (en) 2024-10-23
TW202417044A (en) 2024-05-01
UY40364A (en) 2024-02-15
MX2025000682A (en) 2025-03-07
JOP20250015A1 (en) 2025-01-23
ZA202500495B (en) 2025-08-27
DOP2025000008A (en) 2025-02-28
PE20251691A1 (en) 2025-07-02
MA70850A1 (en) 2025-10-31
CL2025000215A1 (en) 2025-06-13
CN119997972A (en) 2025-05-13
PY2357704A (en) 2024-05-16

Similar Documents

Publication Publication Date Title
MX390954B (en) COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PROGRAMMED DEATH 1 (PD-1) ANTIBODY AND ANOTHER ANTIBODY.
CR20190403A (en) A PHARMACEUTICAL COMPOSITION INCLUDING AN ANTI-C5 ANTIBODY AGAINST A C5-RELATED DISEASE AND A PRODUCT OF THE SAME
MX2020008445A (en) Methods for treating cancer with anti-pd-1 antibodies.
BR112018000212A2 (en) combined use of anti pd-1 and anti m-csf antibodies in cancer treatment
UY40003A (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
CL2024002767A1 (en) Nlrp3 modulators
MX2021000516A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease.
CO2022014499A2 (en) nlrp3 modulators
DOP2025000008A (en) PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE
CL2024003729A1 (en) Combination therapy of anti-PD-1 active agent, anti-TIM-3 active agent, and anti-LAG-3 active agent to treat cancer.
ECSP23076276A (en) METHODS FOR THE TREATMENT OF CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
CL2024000669A1 (en) Antibodies capable of binding to CD27, variants and their uses
CO2023017186A2 (en) Crystalline forms of trofinetide
CO2022014853A2 (en) Novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2h-chromen-2-on-7-yl sulfate and use thereof
CL2023003209A1 (en) Pharmaceutical composition of pembrolizumab and its use
CO2023014650A2 (en) Dosage and administration of recombinant l-asparaginase
ECSP22092205A (en) LEVILIMAB AQUEOUS PHARMACEUTICAL COMPOSITION AND ITS USE
BR112022021105A2 (en) DOSAGE REGIME TO TREAT A CSF-1R MODULATED DISEASE
PL436660A1 (en) Pharmaceutical composition for cancer treatment
MX2022011651A (en) Method for treating diabetes.
MX2022001083A (en) PEPTIDED AMPHIPHYLIC LIPID MICELLES (PALM) FOR TREATMENT OF PERIPHERAL NEUROPATHY INDUCED BY CHEMOTHERAPY RELATED TO CANCER TREATMENT.
BR112022010488A2 (en) PHARMACEUTICAL FORMULATION, USE OF PHARMACEUTICAL FORMULATION, AND METHOD FOR TREATMENT OF A PATIENT
MX2025013233A (en) POLYMORPHIC FORMS AND FORMULATIONS OF LERIGLITAZONE
MX2024009564A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT THAT INCLUDES FUSION PROTEIN THAT INCLUDES IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF.
MX2026001145A (en) Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same